Evidence map›Paper›PMID 35241127›Full record

ReviewGenome biology2022

Towards accurate and reliable resolution of structural variants for clinical diagnosis.

Zhichao Liu, Ruth Roberts, Timothy R Mercer, Joshua Xu, Fritz J Sedlazeck, Weida Tong

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Genome biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
17.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Journal of medical genetics · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Compound Heterozygous Structural Variants in Cases with Unsolved PRKN-Associated Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  11. Article
  12. Article
  13. Population-scale Long-read Sequencing in themedRxiv : the preprint server for health sciences · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Zhichao LiuNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.
Ruth RobertsApconiX, BioHub at Alderley Park, Alderley Edge, SK10 4TG, UK.
Timothy R MercerAustralian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD, Australia.
Joshua XuNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.
Fritz J SedlazeckHuman Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. fritz.sedlazeck@bcm.edu.
Weida TongNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA. Weida.Tong@fda.hhs.gov.ORCID http://orcid.org/0000-0003-3488-6148
National Center for Toxicological Research · USBaylor College of Medicine · USGarvan Institute of Medical Research · AUUniversity of Birmingham · GB

Funding

Genomic Architecture of Common Disease in Diverse Populations: WGS of Ongoing Hemorrhagic Stroke Study SupplementUM1HG008898 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2016 to 2020
$77.0M
Frequency of variants of unknown significance by ancestry groups in the All of Us Research Program cohortU01HG011758 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI RICHARD A GIBBS, JAMES R. LUPSKI · 2021 to 2026
$13.8M
NHGRI NIH HHS U01 HG011758NHGRI NIH HHS UM1 HG008898
6 · The paper itself

Abstract

Structural variants (SVs) are a major source of human genetic diversity and have been associated with different diseases and phenotypes. The detection of SVs is difficult, and a diverse range of detection methods and data analysis protocols has been developed. This difficulty and diversity make the detection of SVs for clinical applications challenging and requires a framework to ensure accuracy and reproducibility. Here, we discuss current developments in the diagnosis of SVs and propose a roadmap for the accurate and reproducible detection of SVs that includes case studies provided from the FDA-led SEquencing Quality Control Phase II (SEQC-II) and other consortium efforts.

Indexed as

Genomic Structural VariationPhenotypeReproducibility of Results

Identifiers

PMID35241127
PMCPMC8892125
OpenAlexW4214821232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.